Mayne Banks On Nextstellis As Generics Business Suffers

Company Sees 6% Decline In Revenues But Dermatology Portfolio Continues To Grow

 
• By Akriti Seth
  
Progress
Mayne anticipates growing in the next half on the back of new launches • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business